#TransCode_Therapeutics
LightNews LightNews
newsen.bsky.social
TransCode Therapeutics Launches Phase 2a Trial of TTX-MC138 for Colorectal Cancer Patients#USA#Boston#Colorectal_Cancer#TTX-MC138#TransCode_Therapeutics
TransCode Therapeutics Launches Phase 2a Trial of TTX-MC138 for Colorectal Cancer Patients
TransCode Therapeutics has begun Phase 2a trials for TTX-MC138, targeting ctDNA-positive colorectal cancer patients after therapy. The study aims to explore potential cancer recurrence reduction.
third-news.com
May 27, 2026 at 12:39 PM
newsen.bsky.social
TransCode's Groundbreaking License Agreement for Innovative Oncolytic Immunotherapy Platform#USA#Boston#Immuno-Oncology#TransCode_Therapeutics#UIO-524
TransCode's Groundbreaking License Agreement for Innovative Oncolytic Immunotherapy Platform
TransCode Therapeutics has secured an exclusive license for next-gen oncolytic immunotherapy, enhancing cancer treatment options. Discover the potential impact on patients!
third-news.com
March 3, 2026 at 1:43 PM
newsen.bsky.social
TransCode Therapeutics Welcomes Dr. Anna Moore as Chair of Scientific Advisory Board and Partners with MSU#United_States#Boston#TransCode_Therapeutics#Michigan_State_University#Dr._Anna_Moore
TransCode Therapeutics Welcomes Dr. Anna Moore as Chair of Scientific Advisory Board and Partners with MSU
TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, alongside a research agreement with Michigan State University.
third-news.com
April 27, 2026 at 12:15 PM
newsen.bsky.social
TransCode Therapeutics Announces Major Leadership Changes and Transitions#USA#Boston#oncology#TransCode_Therapeutics#RNA-based_therapies
TransCode Therapeutics Announces Major Leadership Changes and Transitions
TransCode Therapeutics has announced a significant leadership transition, marking the retirement of CFO Tom Fitzgerald and appointing John Tattory as Interim CFO.
third-news.com
September 10, 2026 at 8:14 PM
newsen.bsky.social
TransCode Therapeutics Unveils Promising Results for TTX-MC138 in Breast Cancer Research Publication#USA#Boston#TTX-MC138#microRNA-10b#TransCode_Therapeutics
TransCode Therapeutics Unveils Promising Results for TTX-MC138 in Breast Cancer Research Publication
TransCode Therapeutics has recently published vital findings about TTX-MC138, showcasing its potential to improve survival in breast cancer bone metastasis. This innovative treatment targets microRNA-10b, proving effective in preclinical models.
third-news.com
August 31, 2026 at 12:21 PM
newsen.bsky.social
TransCode Therapeutics Secures Flexible Financing to Propel Innovative Cancer Treatments Forward#USA#Boston#TTX-MC138#TransCode_Therapeutics#RNA_cancer_therapy
TransCode Therapeutics Secures Flexible Financing to Propel Innovative Cancer Treatments Forward
TransCode Therapeutics has secured up to $20 million in flexible financing to support its pioneering cancer immunotherapy, extending its operational runway into 2028.
third-news.com
April 7, 2026 at 1:04 PM
newsen.bsky.social
TransCode Therapeutics Publishes Groundbreaking Research on RIG-I Immunotherapy for Cancer Treatment#USA#cancer_therapy#Boston#TransCode_Therapeutics#RIG-I_agonist
TransCode Therapeutics Publishes Groundbreaking Research on RIG-I Immunotherapy for Cancer Treatment
TransCode Therapeutics published a pivotal study on RIG-I immunotherapy, showcasing its potential in precision cancer treatment and imaging.
third-news.com
February 23, 2026 at 1:07 PM
newsen.bsky.social
TransCode Therapeutics and Quantum Leap Submit IND Amendment for Phase 2a Trial of TTX-MC138#USA#Boston#TTX-MC138#TransCode_Therapeutics#Quantum_Leap
TransCode Therapeutics and Quantum Leap Submit IND Amendment for Phase 2a Trial of TTX-MC138
TransCode Therapeutics in collaboration with Quantum Leap Healthcare has submitted an IND amendment for their Phase 2a clinical trial evaluating TTX-MC138. This step aims to combat advanced colorectal cancer.
third-news.com
February 5, 2026 at 1:06 PM
newsen.bsky.social
TransCode Therapeutics Shares Promising Preclinical Findings for TTX-MC138 in Glioblastoma Treatment#USA#Boston#Glioblastoma#TTX-MC138#TransCode_Therapeutics
TransCode Therapeutics Shares Promising Preclinical Findings for TTX-MC138 in Glioblastoma Treatment
TransCode Therapeutics has announced key preclinical findings on TTX-MC138, highlighting its potential in treating aggressive glioblastoma and improving patient survival rates.
third-news.com
January 6, 2026 at 1:18 PM
newsen.bsky.social
TransCode Therapeutics Welcomes Jack E. Stover to its Board of Directors#USA#Boston#TransCode_Therapeutics#RNA#Jack_E._Stover
TransCode Therapeutics Welcomes Jack E. Stover to its Board of Directors
TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, enhancing its strategic leadership in cancer treatment.
third-news.com
December 22, 2025 at 1:20 PM
newsen.bsky.social
TransCode Therapeutics Unveils Promising Phase 1a Results for TTX-MC138 at ESMO Congress#USA#Boston#TTX-MC138#TransCode_Therapeutics#Phase_1a_Trial
TransCode Therapeutics Unveils Promising Phase 1a Results for TTX-MC138 at ESMO Congress
TransCode Therapeutics reported encouraging preliminary data from its Phase 1a trial of TTX-MC138 focusing on metastatic diseases. The trial shows a robust safety profile and promising efficacy.
third-news.com
October 14, 2025 at 12:55 PM
newsen.bsky.social
TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition#United_States#San_Diego#TransCode_Therapeutics#Polynoma#CK_Life_Sciences
TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition
TransCode Therapeutics announced a significant acquisition of Polynoma, enhancing its oncology portfolio with a unique immuno-oncology solution. This transaction includes a $25 million financing to support future advancements.
third-news.com
October 8, 2025 at 12:18 PM
newsen.bsky.social
TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq#United_States#Stock_Split#Boston#TransCode_Therapeutics#RNA_oncology
TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq
TransCode Therapeutics has announced a reverse stock split of 1-for-28, aimed at increasing its stock price to meet Nasdaq listing requirements. The split takes effect on May 15, 2025.
third-news.com
May 5, 2025 at 9:16 PM
newsen.bsky.social
TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Meet Nasdaq Listing Requirements#USA#NASDAQ#Boston#TransCode_Therapeutics#RNA_Oncology_Company
TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Meet Nasdaq Listing Requirements
TransCode Therapeutics has announced a reverse stock split of 1-for-28 to comply with Nasdaq's listing requirements and boost share price.
third-news.com
May 2, 2025 at 8:22 PM
newsen.bsky.social
TransCode Therapeutics: Significant Advances in Phase 1a Clinical Trial for Metastatic Cancer Treatment#USA#Boston#TTX-MC138#TransCode_Therapeutics#metastatic_cancer
TransCode Therapeutics: Significant Advances in Phase 1a Clinical Trial for Metastatic Cancer Treatment
TransCode Therapeutics has reported promising progress in its Phase 1a clinical trial for metastatic cancer, with no significant toxicities observed, showcasing the therapeutic potential of TTX-MC138.
third-news.com
May 1, 2025 at 1:47 PM
newsen.bsky.social
TransCode Therapeutics Urges Shareholders to Support a Reverse Stock Split Proposal#USA#Boston#Stockholders#Reverse_Stock_Split#TransCode_Therapeutics
TransCode Therapeutics Urges Shareholders to Support a Reverse Stock Split Proposal
TransCode Therapeutics, Inc. invites shareholders to vote on a pivotal proposal for a reverse stock split, crucial for maintaining NASDAQ compliance.
third-news.com
April 16, 2025 at 11:32 AM
newsen.bsky.social
TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138#United_States#Boston#RNA_Therapeutics#TTX-MC138#TransCode_Therapeutics
TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138
TransCode Therapeutics has announced the initial dosing of a patient in the fourth cohort of its Phase 1 trial for the TTX-MC138 therapy, aimed at treating metastatic cancer.
third-news.com
March 27, 2025 at 8:46 PM
newsen.bsky.social
TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations#USA#Boston#RNA_Therapeutics#TTX-MC138#TransCode_Therapeutics
TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations
TransCode Therapeutics has successfully closed a registered direct stock offering, raising $10 million for advancing RNA therapeutic research and development.
third-news.com
March 26, 2025 at 8:13 AM
newsen.bsky.social
TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development#United_States#Boston#TTX-MC138#TransCode_Therapeutics#RNA_oncology
TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development
TransCode Therapeutics has announced a direct offering to raise funds for cancer research. The offering is set to close on March 25, 2025.
third-news.com
March 24, 2025 at 3:20 AM
newsen.bsky.social
TransCode Therapeutics Holds Special Meeting to Discuss Key Proposals for Shareholders#United_States#Boston#RNA_Therapeutics#TransCode_Therapeutics#Nasdaq_RNAZ
TransCode Therapeutics Holds Special Meeting to Discuss Key Proposals for Shareholders
TransCode Therapeutics recently concluded a special meeting where shareholders voted on critical proposals regarding share issuance and meeting adjournments.
third-news.com
February 25, 2025 at 9:21 PM
newsen.bsky.social
TransCode Therapeutics Postpones Special Meeting, Focuses on Shareholder Engagement for Future Votes#United_States#Boston#Special_Meeting#TransCode_Therapeutics#RNA_oncology
TransCode Therapeutics Postpones Special Meeting, Focuses on Shareholder Engagement for Future Votes
TransCode Therapeutics has announced the adjournment of its special meeting to February 25, 2025, to gather more shareholder votes on important proposals, emphasizing shareholder participation.
third-news.com
February 4, 2025 at 9:32 PM
newsen.bsky.social
TransCode Therapeutics Doses First Patient in Latest Cancer Clinical Trial Phase#United_States#Boston#TTX-MC138#TransCode_Therapeutics#Phase_1_Trial
TransCode Therapeutics Doses First Patient in Latest Cancer Clinical Trial Phase
TransCode Therapeutics has announced that the first patient in Cohort 3 has been dosed in its Phase 1 clinical trial of TTX-MC138, its leading RNA therapeutic candidate for cancer treatment.
third-news.com
January 14, 2025 at 1:40 PM
newsen.bsky.social
TransCode Therapeutics Successfully Meets Nasdaq Listing Compliance Requirements#United_States#NASDAQ#Boston#TransCode_Therapeutics#RNA_oncology
TransCode Therapeutics Successfully Meets Nasdaq Listing Compliance Requirements
TransCode Therapeutics has regained Nasdaq compliance with listing requirements, signaling a positive future for its cancer treatment innovations.
third-news.com
January 7, 2025 at 1:45 PM